BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush reiterated a Buy rating on the stock and has a $94.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong’s rating is based on BioMarin Pharmaceutical’s strong financial performance and promising pipeline developments. The company exceeded expectations in its second-quarter results for 2025, with both total net product revenues and diluted EPS surpassing consensus estimates. This strong execution has led to an upward revision in the full-year guidance, reflecting management’s confidence in continued sales growth and operational efficiency.
Additionally, BioMarin’s advancements in its product pipeline, particularly with BMN 333, are noteworthy. The positive initial pharmacokinetic data from the ongoing Phase 1 study suggests potential for maintaining a lead in skeletal indications, with further studies planned to support future launches. The company’s strategic efforts in expanding its market reach and developing treatments for conditions like achondroplasia and hypochondroplasia further bolster its growth prospects, justifying the Buy rating.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $120.00 price target.